Cite
HARVARD Citation
Robinson, J. et al. (2016). Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis. pp. e231-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Robinson, J. et al. (2016). Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis. pp. e231-. [Online].